LAM
NBIX icon

LECAP Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

LECAP Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,072
Closed -$930K – 371
2024
Q3 		$930K Buy
8,072
+2,412
+43% +$331K 0.2% 188
2024
Q2 		$779K Buy
+5,660
New +$776K 0.17% 205

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LECAP Asset Management's NBIX Position: Q4 2024 in Review

LECAP Asset Management sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 8,072 shares — an estimated $930K sold.

LECAP Asset Management first reported a position in NBIX in Q2 2024 and held it in 2 quarters. The position peaked at $930K in Q3 2024. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • LECAP Asset Management reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • LECAP Asset Management sold 8,072 Neurocrine Biosciences shares in Q4 2024, an estimated $930K.
  • LECAP Asset Management first reported a position in Neurocrine Biosciences in Q2 2024 and held it in 2 quarters.
  • LECAP Asset Management's Neurocrine Biosciences position peaked at $930K in Q3 2024.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on LECAP Asset Management's 13F filing for Q4 2024, filed 28 Jan 2025.